{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:44:24Z","timestamp":1762868664122,"version":"build-2065373602"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2019JJ50973"],"award-info":[{"award-number":["2019JJ50973"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771364",":81801203"],"award-info":[{"award-number":["81771364",":81801203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2021.103394","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T21:27:16Z","timestamp":1636493236000},"page":"103394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?"],"prefix":"10.1016","volume":"58","author":[{"given":"Haobing","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103394_bib0001","unstructured":"Eculizumab prescribing information 2020."},{"key":"10.1016\/j.msard.2021.103394_bib0002","unstructured":"Rituximab prescribing information 2020."},{"key":"10.1016\/j.msard.2021.103394_bib0003","unstructured":"Mycophenolate mofetil prescribing information 2020."},{"year":"2020","series-title":"Vital surveillances: the Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)\u2014China","key":"10.1016\/j.msard.2021.103394_bib0004"},{"year":"2020","series-title":"Since January 2020 Elsevier has Created a COVID-19 Resource Centre With Free Information in English and Mandarin on the Novel Coronavirus COVID- 19","author":"Lai","key":"10.1016\/j.msard.2021.103394_bib0005"},{"issue":"2","key":"10.1016\/j.msard.2021.103394_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103394_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102249","article-title":"Current and emerging therapeutics for neuromyelitis optica spectrum disorder: relevance to the COVID-19 pandemic","volume":"44","author":"Abboud","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"13","key":"10.1016\/j.msard.2021.103394_bib0008","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0961203309345730","article-title":"Transverse myelitis and vaccines: a multi-analysis","volume":"18","author":"Agmon-Levin","year":"2009","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230869","article-title":"No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab","volume":"15","author":"Alashkar","year":"2020","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.msard.2021.103394_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001060","article-title":"Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders","volume":"8","author":"Apostolos-Pereira","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103394_bib0011","doi-asserted-by":"crossref","unstructured":"Asgari, N., Lillevang, S., Skejoe, H., Falah, M., Stenager, E., Kyvik, K.J.N., 2011. A population-based study of neuromyelitis optica in Caucasians. 76(18), 1589\u20131595.","DOI":"10.1212\/WNL.0b013e3182190f74"},{"key":"10.1016\/j.msard.2021.103394_bib0012","first-page":"1","article-title":"Covid-19 infection-induced neuromyelitis optica: a case report","author":"Batum","year":"2020","journal-title":"Int. J. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0013","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2021.103394_bib0014","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/1352458518776584","article-title":"Treating neuromyelitis optica with azathioprine: 20-year clinical practice","volume":"25","author":"Bichuetti","year":"2019","journal-title":"Mult. Scler."},{"issue":"22","key":"10.1016\/j.msard.2021.103394_bib0015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","volume":"94","author":"Brownlee","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.103394_bib0017","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2021.103394_bib0018","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clineuro.2016.03.023","article-title":"Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations","volume":"144","author":"Chang","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"12","key":"10.1016\/j.msard.2021.103394_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5120107","article-title":"Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: insights from Preclinical Studies","volume":"5","author":"Chen","year":"2016","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2021.103394_bib0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.msard.2019.01.052","article-title":"A case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination","volume":"30","author":"Cho","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2021.103394_bib0021","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.msard.2021.103394_bib0022","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0023","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1756285616632653","article-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","volume":"9","author":"Collongues","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103394_bib0024","article-title":"COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: cause or coincidence?","author":"Correa","year":"2020","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2021.103394_bib0025","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"10206","key":"10.1016\/j.msard.2021.103394_bib0026","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.msard.2021.103394_bib0027","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: a Systematic Review and Meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103394_bib0028","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/art.37966","article-title":"Glucocorticoids Suppress T Cell Function by Up-Regulating MicroRNA-98","volume":"65","author":"Davis","year":"2013","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.msard.2021.103394_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102474","article-title":"Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report","volume":"46","author":"de Ruijter","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103394_bib0030","article-title":"Neuromyelitis optica associated with yellow fever vaccination","author":"Esmanhotto","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2021.103394_bib0031","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/1735-1995.200275","article-title":"Efficacy and safety of rituximab in neuromyelitis optica: review of evidence","volume":"22","author":"Etemadifar","year":"2017","journal-title":"J. Res. Med. Sci."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0032","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000787","article-title":"Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders","volume":"7","author":"Fan","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0033","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and Disease-Modifying Antirheumatic Drugs: practical Implications for the Rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"2","key":"10.1016\/j.msard.2021.103394_bib0035","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/j.1468-1331.2010.03204.x","article-title":"Neuromyelitis optica after Japanese encephalitis vaccination","volume":"18","author":"Furukawa","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103394_bib0036","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.msard.2021.103394_bib0037","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/ni.1900","article-title":"Control systems and decision making for antibody production","volume":"11","author":"Goodnow","year":"2010","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0038","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-015-0124-x","article-title":"Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists","volume":"16","author":"Goyal","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0039","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000009619","article-title":"Miller Fisher syndrome and polyneuritis cranialis in COVID-19","volume":"95","author":"Guti\u00e9rrez-Ortiz","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103394_bib0040","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/TCRM.S261753","article-title":"Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era","volume":"16","author":"Hamdy","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"issue":"11","key":"10.1016\/j.msard.2021.103394_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA Vaccines-How Far From Clinical Use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. Sci."},{"year":"2020","series-title":"Update On Neuromyelitis Optica Spectrum Disorder","author":"Holroyd","key":"10.1016\/j.msard.2021.103394_bib0042"},{"issue":"10223","key":"10.1016\/j.msard.2021.103394_bib0043","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.msard.2021.103394_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02066","article-title":"Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: a Prospective Multicenter Study in South China","volume":"9","author":"Huang","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2021.103394_bib0045","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0046","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2021.103394_bib0047","doi-asserted-by":"crossref","unstructured":"Jenkins, M., Khoruts, A., Ingulli, E., Mueller, D., McSorley, S., Reinhardt, R., Itano, A., Pape, K.J.A.r.o.i., 2001. In vivo activation of antigen-specific CD4 T cells. 19, 23\u201345.","DOI":"10.1146\/annurev.immunol.19.1.23"},{"key":"10.1016\/j.msard.2021.103394_bib0048","doi-asserted-by":"crossref","unstructured":"Jiao, Y., Fryer, J., Lennon, V., Jenkins, S., Quek, A., Smith, C., McKeon, A., Costanzi, C., Iorio, R., Weinshenker, B., Wingerchuk, D., Shuster, E., Lucchinetti, C., Pittock, S.J.N., 2013. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. 81(14), 1197\u20131204.","DOI":"10.1212\/WNL.0b013e3182a6cb5c"},{"key":"10.1016\/j.msard.2021.103394_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.msard.2021.103394_bib0051","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of Neuromyelitis Optica: review and Recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0052","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2169\/internalmedicine.51.5636","article-title":"Elderly-onset neuromyelitis optica which developed after the diagnosis of prostate adenocarcinoma and relapsed after a 23-valent pneumococcal polysaccharide vaccination","volume":"51","author":"Kitazawa","year":"2012","journal-title":"Intern. Med."},{"issue":"2","key":"10.1016\/j.msard.2021.103394_bib0053","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103394_bib0054","doi-asserted-by":"crossref","unstructured":"Kline, L., Margulies, S., Oh, S.J.A.o.n., 1982. Optic neuritis and myelitis following rubella vaccination. 39(7), 443\u2013444.","DOI":"10.1001\/archneur.1982.00510190061022"},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.103394_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jns.2010.10.013","article-title":"A serological analysis of viral and bacterial infections associated with neuromyelitis optica","volume":"300","author":"Koga","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2021.103394_bib0056","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103394_bib0057","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13756-019-0475-9","article-title":"Pneumonia in hospitalized neurologic patients: trends in pathogen distribution and antibiotic susceptibility","volume":"8","author":"Lee","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.msard.2021.103394_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103189","article-title":"Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases","volume":"55","author":"Lotan","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103394_bib0059","article-title":"Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders","author":"Louapre","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol."},{"issue":"34","key":"10.1016\/j.msard.2021.103394_bib0062","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2021.103394_bib0063","doi-asserted-by":"crossref","unstructured":"MacLennan, I., Toellner, K., Cunningham, A., Serre, K., Sze, D., Z\u00fa\u00f1iga, E., Cook, M., Vinuesa, C.J.I.r., 2003. Extrafollicular antibody responses. 194, 8\u201318.","DOI":"10.1034\/j.1600-065X.2003.00058.x"},{"key":"10.1016\/j.msard.2021.103394_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102482","article-title":"Beyond COVID-19: DO MS\/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?","volume":"46","author":"Maillart","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103394_bib0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Mealy","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2021.103394_bib0066","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2021.103394_bib0067","doi-asserted-by":"crossref","unstructured":"Menge, T., Cree, B., Saleh, A., Waterboer, T., Berthele, A., Kalluri, S., Hemmer, B., Aktas, O., Hartung, H., Methner, A., Kieseier, B.J.N., 2012. Neuromyelitis optica following human papillomavirus vaccination. 79(3), 285\u2013287.","DOI":"10.1212\/WNL.0b013e31825fdead"},{"issue":"11","key":"10.1016\/j.msard.2021.103394_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102669","article-title":"Screening neuromyelitis optica patients for COVID-19 infection","volume":"19","author":"Mirmosayyeb","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0069","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001046","article-title":"A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: a Pilot Analysis","volume":"8","author":"Money","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103394_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2020.03.062","article-title":"A first case of meningitis\/encephalitis associated with SARS-Coronavirus-2","volume":"94","author":"Moriguchi","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.msard.2021.103394_bib0071","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s00415-020-09934-w","article-title":"Acute transverse myelitis after COVID-19 pneumonia","volume":"267","author":"Munz","year":"2020","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0072","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001057","article-title":"COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: from the COViMS Registry","volume":"8","author":"Newsome","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2021.103394_bib0073","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103394_bib0074","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2021.103394_bib0075","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.rdc.2017.06.007","article-title":"Neuromyelitis Optica","volume":"43","author":"Patterson","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"7","key":"10.1016\/j.msard.2021.103394_bib0076","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2021.103394_bib0077","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"The Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0078","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"15","key":"10.1016\/j.msard.2021.103394_bib0079","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.17116\/patol20188005156","article-title":"[Autoimmune\/inflammatory syndrome induced by adjuvants]","volume":"80","author":"Radenska-Lopovok","year":"2018","journal-title":"Arkh. Patol."},{"key":"10.1016\/j.msard.2021.103394_bib0081","doi-asserted-by":"crossref","unstructured":"Reyfman, P., Walter, J., Joshi, N., Anekalla, K., McQuattie-Pimentel, A., Chiu, S., Fernandez, R., Akbarpour, M., Chen, C., Ren, Z., Verma, R., Abdala-Valencia, H., Nam, K., Chi, M., Han, S., Gonzalez-Gonzalez, F., Soberanes, S., Watanabe, S., Williams, K., Flozak, A., Nicholson, T., Morgan, V., Winter, D., Hinchcliff, M., Hrusch, C., Guzy, R., Bonham, C., Sperling, A., Bag, R., Hamanaka, R., Mutlu, G., Yeldandi, A., Marshall, S., Shilatifard, A., Amaral, L., Perlman, H., Sznajder, J., Argento, A., Gillespie, C., Dematte, J., Jain, M., Singer, B., Ridge, K., Lam, A., Bharat, A., Bhorade, S., Gottardi, C., Budinger, G., Misharin, A.J.A.j.o.r., medicine, c.c., 2019. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. 199(12), 1517\u20131536.","DOI":"10.1164\/rccm.201712-2410OC"},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0082","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/BOR.0000000000000603","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"31","author":"Romeo","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0083","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2021.103394_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102259","article-title":"Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"42","author":"Salama","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103394_bib0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.msard.2016.11.009","article-title":"NMOSD triggered by yellow fever vaccination - An unusual clinical presentation with segmental painful erythema","volume":"11","author":"Schoberl","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103394_bib0088","unstructured":"Shoenfeld, Y., Zandman-Goddard, G., Stojanovich, L., Cutolo, M., Amital, H., Levy, Y., Abu-Shakra, M., Barzilai, O., Berkun, Y., Blank, M., de Carvalho, J., Doria, A., Gilburd, B., Katz, U., Krause, I., Langevitz, P., Orbach, H., Pordeus, V., Ram, M., Toubi, E., Sherer, Y.J.T.I.M.A.j.I., 2008. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases\u20132008. 10(1), 8\u201312."},{"issue":"4","key":"10.1016\/j.msard.2021.103394_bib0089","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"The Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.msard.2021.103394_bib0091","unstructured":"Tishler, M., Shoenfeld, Y.J.T.I.M.A.j.I., 2004. Vaccination may be associated with autoimmune diseases. 6(7), 430\u2013432."},{"key":"10.1016\/j.msard.2021.103394_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102347","article-title":"The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study","volume":"45","author":"Tomczak","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0093","first-page":"76","article-title":"The efficacy of rituximab in the therapy of neuromyelitis optica in a patient with Sjogren\u2019s syndrome: case-report and literature review","volume":"90","author":"Torgashina","year":"2018","journal-title":"Ter. Arkh."},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.103394_bib0094","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2021.103394_bib0095","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"The Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103394_bib0096","article-title":"Neuromyelitis Optica Spectrum Disorder Attack Triggered by Herpes Zoster Infection","volume":"2020","author":"Turco","year":"2020","journal-title":"Mult. Scler. Int."},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0097","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jocn.2012.12.022","article-title":"Neuromyelitis optica: concept, immunology and treatment","volume":"21","author":"Uzawa","year":"2014","journal-title":"J. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2021.103394_bib0098","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","article-title":"Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?","volume":"8","author":"Vadala","year":"2017","journal-title":"EPMA J."},{"issue":"1","key":"10.1016\/j.msard.2021.103394_bib0099","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"8","key":"10.1016\/j.msard.2021.103394_bib0100","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.msard.2021.103394_bib0101","doi-asserted-by":"crossref","first-page":"e00771","DOI":"10.1016\/j.idcr.2020.e00771","article-title":"Guillain-Barre Syndrome associated with SARS-CoV-2 infection","volume":"20","author":"Virani","year":"2020","journal-title":"IDCases"},{"issue":"7","key":"10.1016\/j.msard.2021.103394_bib0102","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2021.103394_bib0103","article-title":"An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development","volume":"26","author":"Wang","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.msard.2021.103394_bib0104","doi-asserted-by":"crossref","unstructured":"Wingerchuk, D., Banwell, B., Bennett, J., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., Jarius, S., Lana-Peixoto, M., Levy, M., Simon, J., Tenembaum, S., Traboulsee, A., Waters, P., Wellik, K., Weinshenker, B., J.N., 2015. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. 85(2), 177\u2013189.","DOI":"10.1212\/WNL.0000000000001729"},{"key":"10.1016\/j.msard.2021.103394_bib0105","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.717111","article-title":"COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: vaccine Hesitancy and Coping Style","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Neurol."},{"issue":"22","key":"10.1016\/j.msard.2021.103394_bib0106","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103394_bib0107","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jocn.2017.10.005","article-title":"Infections in neuromyelitis optica spectrum disorder","volume":"47","author":"Zhong","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2021.103394_bib0108","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","article-title":"Vaccination in Multiple Sclerosis: friend or Foe?","volume":"10","author":"Zrzavy","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:59Z","timestamp":1761901259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":105,"alternative-id":["S2211034821006611"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103394","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103394"}}